NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses

NVX-CoV2373 is an adjuvanted recombinant full-length SARS-CoV-2 spike trimer protein vaccine demonstrated to be protective against COVID-19 in efficacy trials. Here we demonstrate that vaccinated individuals made CD4(+) T cell responses after 1 and 2 doses of NVX-CoV2373, and a subset of individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Rydyznski Moderbacher, Carolyn, Kim, Christina, Mateus, Jose, Plested, Joyce, Zhu, Mingzhu, Cloney-Clark, Shane, Weiskopf, Daniela, Sette, Alessandro, Fries, Louis, Glenn, Gregory, Crotty, Shane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525112/
https://www.ncbi.nlm.nih.gov/pubmed/35943810
http://dx.doi.org/10.1172/JCI160898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525112/
https://www.ncbi.nlm.nih.gov/pubmed/35943810
http://dx.doi.org/10.1172/JCI160898

Ejemplares similares